Group 1 - The market opened higher but retreated, with all three major indices turning negative [1] - The Tianhong Innovation Drug ETF (517380) recorded a trading volume exceeding 22 million yuan by midday [1] - The ETF has seen a cumulative net inflow of nearly 300 million yuan over the last 10 trading days [2] Group 2 - The Tianhong Innovation Drug ETF is the only ETF tracking the Hang Seng-Hu-Kong-Shen Innovation Drug Selected 50 Index, covering the entire industry chain from preclinical research to commercialization [2] - The top ten constituent stocks of the index are heavily weighted towards leading companies such as WuXi AppTec and HengRui Medicine [2] - The 44th JPMorgan Healthcare Conference, a significant event for the global biopharmaceutical industry, took place from January 12 to 15, focusing on biotechnology, biopharmaceuticals, and AI in medicine [2] Group 3 - Zhongtai Securities indicates that the demand for CRO and CDMO in the pharmaceutical sector is gradually recovering, with a simultaneous improvement in profitability and valuation expected [2] - CITIC Construction Investment Securities states that the Chinese pharmaceutical industry has entered a critical phase of "innovation realization and global layout," supported by population and domestic demand [3] - The industry is expected to see opportunities from innovation commercialization, global breakthroughs, policy optimization, and mergers and acquisitions by 2026 [3]
全球生物医药行业“春晚”落幕，创新药ETF天弘（517380）盘中成交额超2200万元，近10日累计“吸金”近3亿元
2 1 Shi Ji Jing Ji Bao Dao·2026-01-16 05:47